Assessment of the Effect of Two Regimens of Milrinone Infusion in Pediatric Patients Undergoing Fontan Procedure: A Randomized Study

Abstract

Objective: The aim of the study was to compare the effect of two different regimens of milrinone on hemodynamics and oxygen saturation in pediatric patients undergoing Fontan procedure. Design: This was a randomized study. Setting: Cardiac centers. Patients: This study included 116 patients undergoing Fontan procedure. Material and Methods: Group E: Milrinone was started as infusion 0.5 µg/kg/min without a loading dose at the beginning of cardiopulmonary bypass (CPB) followed by infusion 0.5–0.75 µg/kg/min in the pediatric cardiac surgical intensive care unit (PSICU). Group L: Milrinone was started as a loading dose 50 µg/kg over 10 min before weaning from CPB followed by infusion 0.5–0.75 µg/kg/min in the PSICU. Measurements: Heart rate, mean arterial blood pressure, central venous pressure, transpulmonary pressure, cardiac index, pharmacological support, lactate level, urine output, oxygen saturation, ICU, and hospital length of stay. Main Results: There were no changes in the heart rate and mean arterial blood pressure (P > 0.05). The increase in the postoperative central venous pressure, transpulmonary pressure and lactate level was lower in Group E than Group L (P < 0.05). The increase in the postoperative cardiac index, oxygen saturation, and urine output was higher in Group E than Group L (P < 0.05). The requirement for pharmacological support was lower in the Group E (P < 0.05). The ICU and hospital length of stay were shorter in the Group E than Group L (P < 0.05). Conclusion: Early use of milrinone during Fontan procedure facilitated the weaning from CPB, decreased the elevation in the central venous pressure, transpulmonary gradient pressure, and the requirement for pharmacological support. Furthermore, it increased the cardiac index and arterial oxygen saturation.

Keywords: Fontan procedure, hemodynamics, milrinone, oxygen saturation, pediatric patients

Introduction

The Fontan procedure is used mainly for patients with complex cardiac malformations such as tricuspid atresia, pulmonary atresia with intact ventricular septum, double inlet ventricle, hypoplastic left heart syndrome, or hypoplastic right heart syndrome. Through Fontan operation, the whole systemic venous return is directed to the pulmonary arteries; and therefore, there is no pulmonary ventricle, so the pulmonary blood flow and preload to the systemic ventricle are critically dependent on the transpulmonary pressure gradient. Systemic vasodilatation is required after the Fontan operation, to reduce afterload on the systemic ventricle and to maintain a low pulmonary vascular resistance to augment the pulmonary blood flow. Milrinone is a Type III phosphodiesterase inhibitor and it is used as an effective medication for the patients with preexisting pulmonary hypertension or depressed postoperative cardiac function as it has inotropic, vasodilatory, and lusitropic effects. Therefore, it produces relaxation of the vascular smooth muscle and improves both systolic and diastolic cardiac function. Its usage has become a first-line choice for patients with various extents of pulmonary hypertension. Milrinone is a drug commonly used to support cardiac output after congenital heart surgery in neonates, infants, and children. In pediatric patients undergoing the Fontan procedure, milrinone is often used in the perioperative period in many centers.

The aim of present study was to compare the effect of two different regimens of milrinone administration on hemodynamics and oxygen saturation in pediatric patients undergoing Fontan procedure.

Material and Methods

After obtaining informed consent and approval of local ethics and research...
committee in two cardiac centers, a double-blind randomized study included 116 pediatric patients (age 4.6–5.8 years) undergoing Fontan procedure. The inclusion criteria included primary Fontan procedure (not redo or revision Fontan procedure), patients with tricuspid atresia, pulmonary atresia with intact ventricular septum, double inlet ventricle, hypoplastic left heart syndrome, hypoplastic right heart syndrome, and the American Society of Anesthesiologists physical status classification system Score III or IV. Exclusion criteria included patients with preoperative pulmonary hypertension, revision surgery for failing Fontan procedure, preoperative low cardiac output syndrome, preexisting renal failure, preexisting thrombocytopenia, preoperative use of milrinone or known allergy to study medication. The concealment of allocation was done using random numbers generated through excel into two equal groups (n = 58 each). The study medication was prepared in 50 ml syringe in the main pharmacy and given to the anesthetist.

**Anesthetic technique**

The patients received Phenergan orally 0.5 mg/kg 2 h before surgery in the wards. Before induction of anesthesia noninvasive monitors (electrocardiography, pulse oximeter, and noninvasive blood pressure) were fixed. Induction of anesthesia was done for all patients by administration of intravenous ketamine (1–2 mg/kg) or thiopentone (3–5 mg/kg) followed by fentanyl (1–2 µg/kg) and pancuronium (0.1 mg/kg). After tracheal intubation, anesthesia was maintained with oxygen (100%), and sevoflurane (1%–3%) in addition to bolus dose of fentanyl (1–2 µg/kg) or morphine (0.1 mg/kg). The end-tidal PaCO₂ was maintained between 30 and 35 mmHg. After induction, invasive monitoring such as arterial line and central venous line were inserted. The cardiopulmonary bypass (CPB) circuit was primed with an average of 250 ml of a combination of plasmalyte, 20% albumin, and whole blood to achieve a hematocrit around 30%. All procedures were done under CPB and with aortic cross-clamping. Before weaning from CPB, the catheter was inserted into left atrium through the right superior pulmonary vein. Furosemide was given as a bolus dose of 5–10 mg in case of need to increase urine output. The patients were classified randomly into two groups:

- **Group E:** (early milrinone group) Milrinone was started as infusion 0.5 µg/kg/min without a loading dose at the beginning of CPB and continued postoperatively (0.5–0.75 µg/kg/min) in the pediatric cardiac surgical intensive care unit (PSICU)
- **Group L:** (late milrinone group) Milrinone was started as a loading dose 50 µg/kg over 10 min before weaning from CPB and continued as infusion (0.5–0.75 µg/kg/min) postoperatively in the PSICU.

During and after weaning from CPB, the oxygen concentration was 50%–100%. After surgery, all patients were transferred to the PSICU and maintained ventilated mechanically on oxygen: Air 50% and positive end-expiratory pressure (PEEP) 0–3 cm H₂O if needed. In ICU, all patients received furosemide (2 mg/kg/day) and spironolactone (2 mg/kg/day) [these diuretics were given through 3 doses in the nasogastric tube].

**Patient monitoring**

For all patients, the following variables were closely monitored; the heart rate, mean arterial pressure, central venous pressure, transpulmonary pressure gradient (difference between central venous pressure and left atrial pressure), cardiac index, pharmacological support (dopamine, epinephrine), pacing, lactate level, urine output, and arterial blood gases. Cardiac index was measured by two-dimensional echocardiography using modified Simpson’s rule to calculate the cardiac output (Stroke volume and heart rate) and dividing the cardiac output over the body surface area. The readings were recorded at the following time points; T1: 15 min after weaning from CPB; T2: At the end of surgery; T3: 6 h after ICU admission; T4: 12 h after ICU admission; T5: 24 h after ICU admission; T6: 36 h after ICU admission; T7: 48 h after ICU admission.

**Outcomes**

The primary outcome was the postoperative hemodynamic stability assessed by heart rate, arterial blood pressure, central venous pressure, transpulmonary pressure gradient, urine output, and the improvement of the postoperative arterial oxygen saturation. The secondary outcome was the safety of the study medications, which was assessed by the occurrence of any adverse events.

**Sample size calculation**

Power analysis was performed using the Chi-square test for independent samples on the frequency of hemodynamic instability and desaturation postoperatively because it was the main outcome variable in the present study. A pilot study was done before starting this study because there are no available data in the literature for the comparison and effect of two regimens of milrinone infusion on hemodynamic instability and desaturation in pediatric patients undergoing Fontan procedure. The results of the pilot study (eight patients in each group) showed that the incidence of hemodynamic instability and desaturation was 25% in early milrinone infusion group, and 50% in late milrinone infusion group. Taking power 0.8, alpha error 0.05, and beta 0.2, a minimum sample size of 58 patients was calculated for each group.

**Statistical analysis**

Data were statistically described in terms of mean ± standard deviation (±SD), or frequencies (number of cases) and percentages when appropriate. Comparison of numerical variables between the study groups was done using the
Student’s t-test for independent samples. Within group comparison of numerical variables was done using paired t-test. For comparing categorical data, Chi-square test was performed. The exact test was used instead when the expected frequency is <5. The \( P < 0.05 \) was considered statistically significant. All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

**Results**

All included patients completed the study. There were no significant differences regarding the demographic data, surgical history, type of congenital cardiac lesions, and data of preoperative catheterization and medications \( P > 0.05 \) [Table 1].

Figure 1 shows the changes in the hemodynamics in the patients of the two groups. There was no difference in the hemodynamics before surgery according to the preoperative data of cardiac catheterization. The heart rate increased in the patients of the two groups, but the difference between the two groups was insignificant \( P > 0.05 \) [Figure 1a]. The changes wereminimal in the mean arterial blood pressure between the two groups \( P > 0.05 \) [Figure 1b]. The central venous pressure increased in the patients of the two groups after weaning from CPB, but the increase was lower in Group E than Group L \( P < 0.05 \) [Figure 1c]. The left atrial pressure increased after weaning from CPB in the patients of the two groups, but the increase was lower in Group E than Group L \( P < 0.05 \) [Figure 1d]. The transpulmonary gradient pressure was lower in patients of Group E than Group L after CPB \( P < 0.05 \) [Figure 1e]. The cardiac index increased in the patients of the two groups after weaning from CPB, but the increase was higher in Group E than Group L \( P < 0.05 \) [Figure 1f]. The arterial oxygen saturation increased after weaning from CPB in the patients of Group E than Group L \( P < 0.05 \) [Figure 1g]. The serum lactate level increased after weaning from CPB in the patients of the two groups, but the increase was lower in Group E than Group L \( P < 0.05 \), and the lactate level decreased after the first postoperative 24 h to be around the preoperative level [Figure 1h].

Table 2 shows the intraoperative data and outcomes of patients of the two groups. There was no difference in the surgical technique, CPB time, aortic cross-clamping time, thorax closure time, postoperative temporary pacemaker, transfused blood products, hemoglobin, or complications. The total milrinone dose was significantly higher in

| Variable                                      | Group E \( n=58 \) | Group L \( n=58 \) | \( P \) |
|-----------------------------------------------|--------------------|--------------------|--------|
| Age (year)                                    | 5.21±1.80          | 5.30±1.75          | 0.785  |
| Gender (male:female)                          | 25:33              | 31:27              | 0.352  |
| Weight (kg)                                   | 16.45±5.36         | 17.25±6.51         | 0.471  |
| Body surface area (m²)                        | 0.56±0.24          | 0.54±0.21          | 0.633  |
| Hemoglobin (g/dL)                             | 16.37±5.30         | 15.85±5.14         | 0.592  |
| Preoperative pacemaker                        | 18                 | 15                 | 0.540  |
| Preoperative diagnosis                        |                    |                    |        |
| Tricuspid atresia                             | 25                 | 22                 | 0.705  |
| Pulmonary atresia with intact septum          | 15                 | 19                 | 0.541  |
| Hypoplastic left ventricle syndrome            | 5                  | 3                  | 0.716  |
| Double-outlet right ventricle                 | 8                  | 10                 | 0.798  |
| Left ventricular double outflow tract         | 5                  | 4                  | 0.728  |
| Prior staging with Glenn procedure            | 48                 | 45                 | 0.642  |
| Ejection fraction (%)                         | 66.82±5.13         | 68.04±4.20         | 0.163  |
| Pre-Fontan catheterization                    |                    |                    |        |
| Preoperative systemic oxygen saturation (%) (T0) | 81.53±4.72        | 82.19±4.25        | 0.430  |
| Preoperative mPAP (mmHg)                      | 15.22±2.16         | 14.89±1.95        | 0.389  |
| Right atrial pressure (CVP) (mmHg) (T0)       | 12.82±2.64         | 11.55±2.32        | 0.116  |
| Left atrial pressure (mmHg) (T0)              | 8.86±2.75          | 9.15±2.59         | 0.559  |
| Transpulmonary gradient (mmHg) (T0)           | 6.10±2.24          | 5.86±2.75         | 0.607  |
| Cardiac index (L/min/m²) (T0)                 | 2.35±1.63          | 2.50±1.68         | 0.626  |
| Heart rate (bpm) (T0)                         | 118.55±13.48       | 117.26±12.90      | 0.599  |
| Mean arterial blood pressure (mmHg) (T0)      | 61.35±10.43        | 62.13±11.27       | 0.699  |
| Serum lactate level (mmol/L) (T0)             | 1.62±0.74          | 1.54±0.72         | 0.556  |
| Furosemide                                   | 58                 | 58                 | 1.000  |
| Aspirin                                      | 48                 | 45                 | 0.642  |

Data are presented as mean±SD, \( n, \% \). Group E: Early milrinone group, Group L: Late milrinone group, mPAP: Mean pulmonary arterial pressure, CVP: Central venous pressure, T0: Preoperative readings, SD: Standard deviation, \( n \): number.
Group E than Group L patients before weaning from CPB ($P < 0.001$) and not associated with hypotension. However, the difference in the total milrinone dose was insignificant after weaning from CPB ($P = 0.194$) or in
the ICU ($P = 0.472$). The number of patients required for nitric oxide and nitroglycerine was lower in Group E than Group L ($P = 0.028$, $P = 0.031$, respectively), and also the required dose of nitric oxide and nitroglycerine was lower in Group E than Group L ($P = 0.011$, $P = 0.037$, respectively). All patients of the two groups required dopamine (the protocol in the cardiac center to use dopamine as the first inotropic agent to facilitate the weaning from CPB) during and after weaning from CPB, but the required dose of dopamine was lower in Group E than Group L ($P = 0.016$). The number of patients required for epinephrine was lower in Group E than Group L ($P = 0.033$). The duration of mechanical ventilation was shorter in the patient’s Group E than Group L ($P = 0.011$). The urine output was higher in Group E than Group L patients ($P = 0.018$). The ICU and hospital length of stay were shorter in the patient’s Group E than Group L ($P = 0.013$, $P = 0.026$, respectively).

**Discussion**

The present study compared two different regimens of milrinone administration in pediatric patients undergoing Fontan procedure. The weaning off patients from CPB was easier in patients of Group E than Group L and the requirement for pharmacological support (nitric oxide, nitroglycerine, dopamine, and epinephrine) was lower in patients of Group E than Group L. The present study showed the following: (1) the cardiac index was higher in patients of Group E than Group L; (2) the increase in the postoperative central venous pressure was lower in patients of Group E than Group L, and this may be related to the decreased pulmonary vascular resistance that improved the

### Table 2: Intraoperative data of patients

| Variable                        | Group E ($n=58$) | Group L ($n=58$) | $P$  |
|---------------------------------|-----------------|-----------------|------|
| Lateral tunnel fenestrated Fontan | 50              | 53              | 0.557|
| Lateral tunnel non-fenestrated Fontan | 2               | 3               | 0.647|
| Extracardiac Fontan            | 6               | 2               | 0.271|
| Cardiopulmonary bypass time (min) | 148.62±73.50    | 155.37±86.81    | 0.652|
| Aortic cross-clamping time (min) | 72.16±21.39     | 77.58±24.30     | 0.204|
| Thorax closure time (min)       | 73.32±8.15      | 76.40±10.28     | 0.076|
| Milrinone dose (mg)             |                 |                 |      |
| Before weaning                  | 1.46±0.24       | 0.96±0.36       | 0.001*|
| After weaning                   | 0.72±0.03       | 0.74±0.05       | 0.194|
| ICU (dose/day)                  | 14.21±4.63      | 14.90±5.62      | 0.472|
| Postoperative temporary pacemaker | 6              | 8               | 0.776|
| Nitric oxide                    |                 |                 |      |
| $n$                            | 13              | 25              | 0.028|
| Dose (ppm)                      | 28.78±4.93      | 31.23±5.35      | 0.011*|
| Nitroglycerine                  |                 |                 |      |
| $n$                            | 6               | 16              | 0.031*|
| Dose (µg/kg/min)                | 4.78±2.15       | 5.69±2.50       | 0.037*|
| Dopamine                        |                 |                 |      |
| $n$                            | 58              | 58              | 1.000|
| Dose (µg/kg/min)                | 6.37±1.45       | 7.10±1.77       | 0.016*|
| Epinephrine                     |                 |                 |      |
| $n$                            | 4               | 13              | 0.033*|
| Dose (µg/kg/min)                | 0.05±0.03       | 0.07±0.05       | 0.010|
| Packed RBC (unit=100 ml)        | 2.30±1.26       | 2.19±1.32       | 0.647|
| Fresh frozen plasma (unit=150 ml) | 1.64±1.14      | 1.76±1.20       | 0.581|
| Platelet (unit=50 ml)           | 3.43±1.47       | 3.56±1.60       | 0.649|
| Cryoprecipitate (unit=15 ml)    | 2.50±1.30       | 2.42±1.22       | 0.732|
| Hemoglobin (g/dL)               | 15.86±5.63      | 15.57±5.90      | 0.787|
| Mechanical ventilation time (h) | 14.55±2.75      | 16.00±3.32      | 0.011|
| Urine output (ml/kg/h)          | 2.79±1.25       | 2.25±1.18       | 0.018|
| Arrhythmia                      | -               | -               |      |
| Pneumonia                       | -               | -               |      |
| ICU length of stay (days)       | 7.32±2.19       | 8.37±2.33       | 0.013|
| Hospital length of stay (days)  | 16.75±3.61      | 18.28±3.70      | 0.026|
| Mortality                       | -               | -               |      |

Data are presented as mean±SD, n. *$P<0.05$: The comparison is significant between the two groups. Group E: Early milrinone group, Group L: Late milrinone group. Packed RBC: Packed red blood cells, ICU: Intensive Care Unit, SD: Standard deviation, n: number
blood flow to the lung; (3) the transpulmonary pressure gradient was lower in patients of Group E than Group L, and this indicates that the pulmonary vascular resistance was lower in Group E than Group L and this finding was reported by Howard et al.\cite{9} therefore, increasing the pulmonary blood flow;\cite{10,11} (4) the left atrial pressure was higher in Group E than Group A, and this increased the filling pressure to left side of the heart and increased the cardiac index in Group E than Group L. Therefore, the increase in the postoperative oxygen saturation was higher in the patients of Group E than Group L. The improvement in the cardiac index and oxygenation led to an improvement of the tissue perfusion as indicated by a lower level of serum lactate and a higher urine output in the patients of Group E than Group L. Early milrinone was infused without bolus dose to avoid the possible problems such as hypotension related to bolus administration and it was found clinically that the early milrinone is more effective than the late milrinone with bolus dose. The total milrinone dose given before weaning from CPB was higher in patients of Group E, and this may lead to the improvement of outcomes with early milrinone administration. One study showed that infusion of milrinone at the beginning of CPB has a potent vasodilator effect and may be associated with improving tissues perfusion as indicated by lower serum lactate levels, higher urine output, and normal mixed venous oxygenation than administration of milrinone after CPB;\cite{12} and that could be explained by study done by Möllhoff et al.\cite{13} They showed that milrinone improved tissue perfusion and the postoperative oxygen transport to the tissue after cardiac surgery as a result of the increased cardiac output and vasodilatation associated with milrinone and the same results were shown by another study.\cite{14}

A similar study in pediatric patients undergoing congenital corrective cardiac surgery showed that early milrinone increased the mean arterial blood pressure, central venous oxygen saturation, urine output and associated with decreased serum lactate level.\cite{15} The good results with early uses of milrinone at the beginning of CPB may be related to the increased level of milrinone in the blood and its effect on the tissue perfusion during and after CPB\cite{16} and other studies showed the same results.\cite{6,7}

Chang et al.\cite{9} reported that milrinone led to the increase in the cardiac index and a decrease in the pulmonary vascular resistance, right and left atrial pressures.

A retrospective analysis of high-risk patients who received milrinone before CPB initiation were weaned easily from CPB and associated with a significant decrease in the pulmonary artery pressure and significant improvement of ventricular function.\cite{17,18}

Other studies showed that the anti-inflammatory properties of milrinone prevent the development inflammatory mediators and acidosis that may affect the pulmonary vascular resistance.\cite{19,21}

Garofalo et al.\cite{22} showed the ventricle had significantly higher stiffness immediately after Fontan operation and milrinone improves the pulmonary circulation by increasing myocardial relaxation.

Other studies found that the use of milrinone after CPB in pediatric patients undergoing Fontan procedure has no effect on the oxygen saturation, elevated pulmonary vascular resistance, central venous pressure, left atrial pressure, transpulmonary pressure gradient, and clinical outcomes after Fontan and the possible causes, (1) a limited amount of milrinone could enter into the pulmonary circulation at the initial stage as a result of a significant shunt to the systemic circulation through the fenestration, secondary-to-high pulmonary vascular resistance, and a lower concentration of milrinone in the pulmonary vascular wall; (2) the optimum concentration in the blood requires maintained infusion to be effective.\cite{3,6,23-26}

Other studies showed that the plasma concentration of a continuous infusion without a bolus reached the same level after 1 h as the concentration in patients who received continuous infusion initiated by a loading dose.\cite{27-29}

Contrary to the result of the present study, Malec et al.\cite{30} reported that milrinone infusion (0.25–0.75 μg/kg/min) after CPB, improved the outcome after Fontan procedure.

The present study recognizes some limitations such as the serum level of milrinone was not measured, as the kits for measurement were not available in the laboratory.

**Conclusion**

Early use of milrinone in patients undergoing Fontan procedure facilitated the weaning from CPB, decreased the elevation in the central venous pressure, transpulmonary gradient pressure, and the requirement for pharmacological support. Furthermore, it increased the cardiac index and arterial oxygen saturation.

**Acknowledgments**

The authors thank all staff nurses in the operative rooms and cardiac surgical ICU for their efforts and performance during the study. The authors appreciate Mr Kashif Siddique who did statistical analysis for the study.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1.  Beghetti M. Fontan and the pulmonary circulation: A potential role for new pulmonary hypertension therapies. Heart 2010;96:911-6.
2.  Kreutzer C, Kreutzer J, Kreutzer GO. Reflections on five decades of the Fontan Kreutzer procedure. Front Pediatr 2013;1:45.
with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg 2006;102:1062-9.

17. Lamarache Y, Perrault LP, Maltais S, Tétucault K, Lambert J, Denault AY, et al. Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg 2007;31:1081-7.

18. Farah P, Ahmad-Ali A, Hanane G, Abbas E. Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children. Inn J Pediatr 2013;23:19-26.

19. Levy JH, Bailey JM, Deeb GM. Intravenous milrinone in cardiac surgery. Ann Thorac Surg 2002;73:325-30.

20. Gong M, Lin XZ, Lu GT, Zheng LJ. Preoperative inhalation of milrinone attenuates inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass. Med Princ Pract 2012;21:30-5.

21. Yamaura K, Okamoto H, Akiyoshi K, Irita K, Tamijima T, Takahashi S, et al. Effect of low-dose milrinone on gastric intramuscal pH and systemic inflammation after hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15:197-203.

22. Garofalo CA, Cabrera SE, Quinn TA, Weinberg AD, Printz BF, Hsu DT, et al. Ventricular diastolic stiffness predicts perioperative morbidity and duration of pleural effusions after the Fontan operation. Circulation 2006;114:156-61.

23. Kurokawa S, Tomita Y, Taneoka M, Iwata S, Doi K, Nomura M. Effects of olprinone on hemodynamics and oxygen delivery in pediatric cardiac surgery: Magnitude of effects and comparison to milrinone. Egypt J Anesth 2013;29:343-50.

24. Meyer S, Gortner L, Brown K, Abdul-Khalig H. The role of milrinone in children with cardiovascular compromise: Review of the literature. Wien Med Wochenschr 2011;161:184-91.

25. Sorensen GK, Ramamoorthy C, Lynn AM, French J, Stevenson JG. Hemodynamic effects of amrinone in children after Fontan surgery. Anesth Analg 1996;82:241-6.

26. Burkhardt BE, Rücker G, Stiller B. Propyllyclic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. Cochrane Database Syst Rev 2015;3:CD009515.

27. Baruch L, Patacsil P, Hameed A, Pina I, Loh E. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J 2001;141:266-73.

28. Shibata T, Suehiro S, Sasaki Y, Hosono M, Nishi S, Kinoshita H, et al. Slow induction of milrinone after coronary artery bypass grafting. Ann Thorac Cardiovasc Surg 2001;7:23-7.

29. Kwak YL, Oh YJ, Shin HK, Yoo KJ, Kim SH, Hong YW, et al. Haemodynamic effects of a milrinone infusion without a bolus in patients undergoing off-pump coronary artery bypass graft surgery. Anaesthesia 2004;59:324-31.

30. Malec E, Schmidt C, Lehner A, Januszewska K. Results of the Fontan operation with no early mortality in 248 consecutive patients. Kardiol Pol 2017;75:255-60.